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Abstract 
HPLC methods for insulin in official monographs require extended runtimes and elevated temperatures. Inter-
laboratory reproducibility of HPLC methods obtained from published literature is an on-going challenge, 
moreso for peptides. This paper serves as a step-by step guide to troubleshoot and establish a validated HPLC 
method for insulin at room temperature using simple UV detectors with minimal run times. A modified 
gradient reversed-phase HPLC was developed for the quantification of recombinant human insulin with UV 
detection at room temperature.  An octadecylsilica column was used as the stationary phase while the mobile 
phase consisted of solution A: 1mmol sodium sulphate and 0.2% triethylamine in water and solution B: 
acetonitrile. The developed method was then validated using International Conference on Harmonisation (ICH) 
guidelines. The calibration curve was linear over a concentration range of 10-1000 µg/mL with correlation 
coefficient of 0.9993, with average recovery percent of 100.89 ± 1.4% and RSD recovery of 0.01. Insulin 
retention time was 3.84 ± 0.08 mins, while LOD and LOQ were estimated at 0.63 and 2.0 µg/mL respectively. 
The developed method conformed to the validation criteria of the ICH guidelines in our laboratories and other 
independent operator laboratories, and can serve as a rapid and effective method for quantifying insulin from 
any sample at room temperature using simple detectors. 
Keywords : Insulin; HPLC validation; ICH guidelines; inter-laboratory reproducibility; method development; 
optimisation, biotech products 
Introduction  
High Performance Liquid Chromatography (HPLC) is an analytical technique used for separation, isolation, and 
quantification of components of a sample [1]. HPLC is often employed for the quantitative analysis of 
pharmaceutical products because chemical methods (such as iodometry or colorimetry) and some 
spectrophotometric methods commonly employed have limited specificity, with chemical methods showing 
lower precision; while gas chromatography cannot be effectively utilised because of the thermolabile nature of 
most pharmaceuticals [2, 3]. Moreso, HPLC allows for rapid analysis of different drugs and their metabolites 
[4].  
The biologically active and circulating form of insulin (Figure 1) is a polypeptide comprising 2 amino acid 
chains linked by two di-sulfide linkages, afforded by the amino acid cysteine. It contains 51 amino acids; 21 
amino acids make up the A chain and 30 make up the B chain; with molecular weight of 5800 Da. A di-
sulphide linkage exists within the A chain [5]. Insulin is administered subcutaneously for the management of 
insulin-dependent diabetes in patients whose pancreas does not produce insulin, or those whose cells have 
low insulin sensitivity. It is also the most important hormone in the regulation of glucose homeostasis in the 
body [6].  
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Figure 1. Primary structure of insulin showing A and B polypeptide chains, with inter- and intra-molecular di-
sulphide bridges [7] 
HPLC has found increasing applications in the isolation and purification of peptides and proteins in recent 
years. Proteins like insulin have been quantified using biological assays in the past. These assays, though 
specific, were limited by their ineffectiveness at detecting very low doses, and could not identify contaminant 
or decomposition products; hence, the increased use of HPLC [8]. However, the chemical nature and size of 
proteins makes their HPLC difficult because various factors, such as temperature and pH, need to be optimised 
[9, 10]. The official monographs (British Pharmacopoeia, United States Pharmacopoeia, European 
Pharmacopoeia) contain methods for the detection and assay of insulin by HPLC, but these methods require 
extended runtimes, or the use of elevated temperature [9, 11]. Various researchers have also employed HPLC 
for quantification of insulin in literature using buffered [9, 10, 12-14] and unbuffered mobile phases [5, 15]. 
However these methods require either the use of elevated temperatures, specialised detectors or resulted in 
long run times. More importantly, difficulty in reproducing methods obtained from published literature in 
different laboratories using different equipment is a constant challenge. The onus therefore is on the 
researcher to develop and validate a suitable reproducible method for quantification of these proteins. The 
said method should ideally be carried out at room temperature, with as few variables as possible. The aim of 
this work therefore was to describe our implementation of a literature derived method and step-by-step 
progression within our laboratory to establish a simple, rapid and effective method for quantification of insulin 
by HPLC, which would be validated by ICH guidelines [16]; and can be reproduced in any laboratory using 
simple UV detectors at room temperature. 
Materials and Methods 
Materials 
 Human recombinant insulin powder, phosphate buffered saline tablets, triethylamine and anhydrous sodium 
sulphate were purchased from Sigma-Aldrich, UK; while o-phosphoric acid and hydrochloric acid were 
purchased from Fisher Scientific, UK. All water used was double distilled. 
Methods 
High Performance Liquid Chromatography (HPLC) Assay 
Gradient RP-HPLC was employed for quantitative analysis of the insulin in solution and was adapted from 
Rajan et al [9]. A Dionex 1100 autosampler (AS50) system, with gradient pump (GP50), UV detector (UVD 
170U) set at 230nm was used, employing a reversed phase RP-C18 analytical column (Phenomenex 110A, 
150x4.6mm, 5µm). The mobile phase consisted of solution A: 1mmol sodium sulphate and 0.2% triethylamine 
in water, pH adjusted to 3.2 with o-phosphoric acid; and solution B: acetonitrile, both filtered under vacuum 
and sonicated [9]. A gentle gradient was run from 75:25 v/v to 60:40 v/v compositions of A:B over 5 mins, and 
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then maintained at 60:40 v/v for 2 minutes. Pump flow rate was 1.5 mL/min, with sample injection volume of 
20 µL. The maximum wavelength of absorption of insulin had been pre-determined using a Unicam UV-visible 
spectrophotometer. Finally a rectilinear (Beer-Lamberts) calibration curve was established for insulin within a 
concentration range of 10-1000 µg/mL dissolved in 0.01N HCl. 
Hplc Assay Validation  
The HPLC method was validated according to ICH guidelines in terms of specificity, accuracy, precision, 
linearity, limits of detection/ quantification and stability of insulin solutions [5, 10].  
Specificity (Identification and Assay)  
20 μL of 200 mg/mL insulin and 0.01N HCl solutions respectively were separately injected into the HPLC 
system, retention time and resulting chromatograms were recorded. Insulin percentage recovery (the 
calculated concentration of insulin relative to the actual concentration used) was calculated using the 
regression equation obtained from linearity experiments below. 
 Linearity  
A Beer-Lamberts calibration curve was developed by plotting mean peak area against insulin concentration. 
Linearity was estimated by computing the regression line of the calibration curve for insulin concentration 
from 10-1000 μg/mL; the correlation coefficient (R2) was calculated.  
 Accuracy  
20 μL aliquots of standard solutions were injected into the HPLC system and the protocol described for 
linearity above followed. The areas under the curve for insulin were recorded and the percentage recovery was 
calculated using the regression equation.  
 Precision  
Operator precision was determined by developing the insulin calibration curve in triplicates. The area under 
the curve was calculated by the HPLC software and relative standard deviation (RSD) was calculated using the 
equation below:  
𝑅𝑆𝐷 =  
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑚𝑒𝑎𝑛
 
Calibration curves were repeated on different days (n=6 or 9) using freshly prepared mobile phase and the 
RSD calculated.  
 Limit of Detection (LOD) and Limit of Quantification (LOQ)  
The LOD and LOQ were determined by the signal-to-noise ratio method [6, 17]. 20 μL of 0.01 N HCl blank was 
injected into the HPLC system twenty times and the mean peak area recorded. The standard deviation of the 
recorded peak areas was multiplied by 3 and 10 to calculate the LOD and LOQ respectively. This was repeated 
twice for two different samples of the blank, in order to validate the obtained results [10].  
 Inter-laboratory method validation 
The validated method was further validated by two independent operators in two different laboratories, using 
different HPLC systems on different days to establish method reproducibility. 
 Stability of Insulin Solutions  
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1000 μg/mL insulin solution was freshly prepared in triplicates and immediately analysed on the HPLC system. 
The solutions were stored in the fridge (2-8 °C) and quantified after three days (72 hrs). The peak areas and 
RSD were recorded. 
Results and Discussion 
HPLC Method Development for quantification of insulin 
The HPLC method development began with a method adapted from Rajan et al [9], employing an isocratic 
elution using a mobile phase comprising 40 volumes of solution A (1mmol sodium sulphate and 0.2% 
triethylamine (TEA) in water, pH adjusted to 3.2 with o-phosphoric acid), and 60 volumes of  solution B 
(acetonitrile); UV detection at 214nm. This method was employed instead of the USP or BP methods, because 
unlike these official methods that were run at elevated temperatures, the chosen method could be run at 
room temperature and had less than half the retention time expected from the BP and USP methods. Thus it 
minimised the possible variables in the HPLC system. Using this system, insulin eluted almost immediately at 
about 1 min (Figure 2).  
 
Figure 2. Sample chromatogram of 0.5 mg/mL insulin in 0.01N HCl at 214nm 
The resulting peak was poorly resolved with an accompanying hump. Running a blank solution (containing 
0.01N HCl) on the HPLC system showed solvent front coming off the column at about the same retention time 
as the drug (Figure 3). Thus, the hump on the insulin chromatogram resulted from the overlapping of the drug 
peak with that of the solvent front [6]. RP-HPLC exploits the interactions between the hydrophobic regions of 
insulin and that of the stationary phase [17]. Fast elution of insulin off the column implied very low affinity of 
insulin for the non-polar column. Generally in reversed phase HPLC, the interaction of hydrophobic analyte 
with the n-alkyl chain of the column would lead to longer retention of the analyte on the column. But the 
presence of steric hindrances in large molecules like insulin may restrict access of the analyte molecules to the 
pores of the stationary phase where these interactions take place [18].  Also, the presence of polar groups (-
NH2, COO–) in the insulin moiety would increase the affinity of insulin for the highly aqueous mobile phase, 
and result in fast elution of insulin. These factors could account for the fast elution of insulin from the mobile 
phase [1].  
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Figure 3. Chromatogram showing elution of the solvent front (blue line) at about the same time as insulin 
(black line) resulting in poor resolution of the insulin peak. 
According to the BP 2013, “insulin is practically insoluble in water” (despite the presence of –OH and –NH 
bonds in the comprising amino acids), however, some authors have reported insulin as highly water soluble 
[6]. It was expected that hydrophobic insulin would interact with the non-polar column (reverse-phase HPLC) 
and would therefore have a longer retention time on the column [1]. As this was not the case as discussed 
above, reducing the non-polar organic modifier in the mobile phase would reduce the interaction of insulin 
with the mobile phase (increased mobile phase polarity), thereby increasing insulin’s interaction with the non-
polar column; ultimately resulting in an increase in insulin retention time [19]. Thus various mobile phase 
compositions (from 50:50 v/v to 75:25 v/v) were employed in an attempt to increase insulin’s retention time, 
and thereby separate the drug peak from that of the solvent front. 
A mobile phase composition of solution A:B 70:30 v/v resulted in  an increase in insulin retention time from 1 
to 2 minutes. However, this minimal shift was not sufficient to completely separate the insulin peak from that 
of the solvent front (Figure 4). This minimal shift in insulin retention time despite a 10% change in mobile 
phase composition could be attributed to the large size of insulin molecules, as large molecules may not easily 
enter the pores of the column to increase column retention [18].   
A further reduction in the amount of the organic modifier used would be expected to further increase the 
retention time of insulin for reasons discussed above. However, the final composition of the mobile phase 
would be highly aqueous and would not effect a complete separation of other impurities or degradation 
products when utilising this method for quantification of insulin from samples. Moreso, highly polar aqueous 
phases may result in poor retention and separation due to the collapse of the octadecyl alkyl side chains in the 
stationary column [20]. Xu et al [6] reported an increase in insulin retention time with increasing acetonitrile 
content of the mobile phase. 
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Figure 4. Insulin chromatograms at various mobile phase compositions. None of the combinations tried were 
able to effectively increase insulin retention time to >2 minutes. 
At this point, it became necessary to run a blind HPLC to determine the exact mobile phase composition 
where insulin elutes off the column. Thus, a gradient HPLC was run from 80 – 20% v/v for solution A and 20 – 
80% v/v for solution B. From Figure 5, it was observed that insulin eluted at about 6 minutes which was 
equivalent to mobile phase composition of 60:40 v/v for solution A:B. Thus, insulin was eluted off the column 
immediately the mobile phase composition turned to 60:40, and using an isocratic system would always 
produce a poorly resolved peak because of interference from the solvent front. Also the resultant peak caused 
an upward shift in the baseline, probably due to the changing gradient. 
 
Figure 5. HPLC chromatogram showing insulin elution at 6minutes upon gradient elution from solution A: 
80:20 TO 20:80. An upward shift in the baseline may be due to the changing concentration gradient. 
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In order to obtain a better resolved insulin peak, we further investigating the role of the mobile phase 
additives to the HPLC quantification. Triethylamine (TEA) was used in the mobile phase to facilitate end-
capping of the free silanol groups on the reversed phase column, resulting in the prevention of band tailing in 
HPLC [21, 22]. However, TEA is easily degraded and has been implicated to interfere with UV absorption 
because it has a high UV-cut off above 190nm. This means that TEA can be picked up by the detector and 
would interfere with the resolution of obtained peaks. Because the column had been described as ‘end-
capped’ by the manufacturers, it would be irrelevant to retain TEA in the mobile phase if it was interfering with 
the results.  Thus, TEA was removed from solution A, and a gradient HPLC repeated with solution A (1mmol 
sodium sulphate in water, pH adjusted to 3.2 with o-phosphoric acid) 80 – 20% and solution B (acetonitrile) 20 
– 80%. The resulting chromatogram produced no peak for insulin even after 30 minutes, signifying the 
importance of TEA for insulin elution. Thus, although a column may be claimed to be end-capped by the 
manufacturers, this process might not completely mop up the free silanol groups. This, as well as column use 
and age, would necessitate the addition of a moiety like TEA to compete with the analyte for the free silanol 
groups on the column. 
Following the unsuccessful reproduction of the HPLC method adapted from the journal article, a return to first 
principles was necessary, and a UV scan was run for 0.5 mg/mL insulin in 0.01N HCl. The spectrum displayed 
two maximum wavelength peaks – a major peak at 230nm and a smaller peak at 275nm (data not shown). 
Thus a HPLC gradient (80:20 to 20:80) was run at 214, 230 and 275 nm respectively. From Figure 6 it can be 
seen that at 214nm, there was an upward shift in the baseline, at 275nm, the insulin peak was highly reduced; 
while at 230nm, a well resolved peak with a relatively stable baseline was achieved. Thus, 230nm was chosen 
as the wavelength for recombinant insulin detection. 
 
Figure 6. Chromatograms showing insulin elution at various wavelength: 214 nm (black), 230 nm (blue) and 
275nm (pink). 
Because insulin eluted off the column immediately the mobile phase composition was 60:40, and this early 
elution resulted in a poorly resolved peak due to the concurrent appearance of the solvent front, isocratic 
HPLC could not be applied to this system.  A gradient (80:20 to 20:80 v/v) HPLC for insulin was run at 230nm 
and resulted in a well resolved peak with a relatively stable baseline, and no interference from the solvent 
front, and which eluted after about 4 minutes (Figure 7). Because it had been established that insulin eluted off 
the column at 60:40 mobile phase composition, it was not necessary to continue the steep 80:20 to 20:80 
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gradient, it seemed necessary to employ a gentle gradient. To determine the optimum gradient for separation, 
the following gradients (Table 1) were run:  
Table 1. Mobile phase compositions employed to optimise insulin elution off the analytical column 
Option 1 Option 2 
0-5 mins: 75:25 - 50:50 
5-7 mins: 50:50 - 50:50 
7-10 mins: 50:50 - 75:25 
 
0-5 mins: 70:30 - 45:55 
5-7 mins: 50:50 - 50:50 
7-10 mins: 50:50 - 75:25 
 
The resulting chromatogram for option 1 showed a well resolved peak, completely separated from the solvent 
front, with a slight shifting of the baseline. Modification of the gradient to option 2 resulted in a poorly 
resolved peak which eluted off the column very fast and showed solvent front interference. Thus the first 
protocol was maintained. 
 
Figure 7. Gradient HPLC for insulin at 230 nm 
Finally, to achieve a sharper peak, the flow rate was increased to 2 mL/min. A sharper insulin peak was 
achieved but it eluted off the column at 2 minutes. Gerber [18] reported that increased flow rate could reduce 
retention times, increase baseline noise and produce narrower peaks. Therefore, flowrate was maintained at an 
average of 1.5 mL/min. The chromatogram for the final method is shown in Figure 8 below: 
9 
 
 
Figure 8. Representative chromatogram showing the developed method for insulin elution employing a gentle 
gradient at 230 nm detection wavelength and 1.5 mL/min flow rate 
HPLC Assay Validation   
 Specificity 
To investigate the specificity of the HPLC method, 20µL each of insulin in 0.01N HCl and the blank (0.01N HCl) 
were separately injected into the HPLC and chromatograms developed. Figure 9 shows the chromatograms of 
insulin and the blank run in triplicate. From this chromatogram, the insulin peak was well resolved with 
retention time of 3.84 ± 0.08, there was no interference from the solvent front which eluted at 1.12 ± 0.04 
mins (Table 2). For use with insulin formulations, it would be necessary to test all excipients of the formulation 
to ensure specificity of the method for insulin quantification in the presence of contaminants. According to 
Gupta [23], an assay shows specificity when the signal measured from the test compound shows no 
interference with signals from other excipients at the test wavelength. As an evaluation of accuracy, insulin 
concentrations ranging from 50 – 500 µg/mL were used to calculate the percentage recovery of insulin using 
the described method. The mean absolute recovery value for insulin was 100.89 ± 1.40% (Table). These results 
connote that the developed method can quantify insulin effectively. However, the effect of dosage form 
excipients on the recovery of insulin using this method will need to be investigated [6]. 
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Figure 9. Representative chromatograms showing selectivity and instrument precision of HPLC method. 
Triplicate measurements of 500 µg/mL insulin solution produced identical peaks that were well resolved from 
that of the blank. 
Table 2. Specificity of insulin HPLC method 
S.N. Sample Retention time (min) % RSD 
1 Insulin 3.84 ± 0.08 2.08 
2 Blank (0.01N HCl) 1.12 ± 0.04 3.66 
 
 Linearity  
A Beer-Lamberts calibration curve (Figure 10Figure) was established for insulin over a concentration range of 
10-1000 µg/mL by plotting the peak area from the chromatograms against the concentration. The regression 
analysis gave the equation of the line as y = 0.0543 - 1.0026, with R2 = 0.9993. Parameters of the regression 
coefficient are presented in Table 3.  The high correlation coefficient connotes a linear relationship between 
peak area and insulin concentration within the proposed range [5, 24]. Therefore, the concentration of insulin 
in any sample can be calculated from this curve using this method.  
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Figure 10. Beer-Lamberts calibration curve for insulin 
Table 3. Factors of the regression equation linking insulin concentration to the analytical response (area under 
the peak) 
S.N. Parameter Value 
 Linearity range, µg/mL 10-1000 
 LOD, µg /mL 0.63 
 LOQ, µg /mL 2.00 
 Slope of regression equation 0.0543 
 Intercept -1.0026 
 Correlation coefficient 0.9993 
 Standard error 0.8099 
 
 Repeatability (instrument and operator precision) 
Instrument precision (accuracy) was determined by injecting the same concentration of insulin solution into 
the HPLC three times and calculating the %RSD. Figure 9 shows the overlapping of the three IND 
chromatograms (lines 1-3), indicating the precision of the instrument. From Table 2, the RSD for insulin and 
the blank were relatively low at 2.01 and 3.66% respectively. Similar results were obtained during validation of 
a HPLC method for insulin reported by Moussa et al [10].  Operator precision was determined by establishing 
the calibration curve in triplicates. %RSD values calculated ranged from 7.7 – 9.76% (Table 4). These values 
were within the limits for precision as reported by Epshtein [24].  
Inter-day precision was determined by establishing calibration curves on different days – results are shown in 
Table 5. The overall %RSD values ranged from 3.3 – 9.3%.  These values for %RSD are within the limits for 
y = 0.0543x - 1.0026 
R² = 0.9993 
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precision. Ephstein  [24] reported that for precision in analysis of pharmaceuticals, %RSD should range 
between 0-15%. 
Table 4. Table highlighting intra-day accuracy and precision parameters of the HPLC method due to high 
%recovery and low RSD (n=3) 
S.N. Insulin conc. 
actual (µg/mL) 
Peak Area 
(mAU) 
RSD 
 
Insulin conc. 
calculated (µg/mL) 
Recovery (%) 
1 50 1.78 ± 0.14 0.07 51.31 ± 2.55 100.56 ± 2.42 
2 100 4.49 ± 0.43 0.10 101.11 ± 7.85 101.38 ± 4.89 
3 200 9.27 ± 0.06 0.06 197.60 ± 10.14 98.80 ± 4.71 
5 500 26.52 ± 2.59 0.10 506.90 ± 47.67 101.11 ± 3.99 
6 1000 53.60 ± 3.72 0.07 1005.57 ± 68.56 102.63 ± 3.30 
Mean % recovery = 100.89 ± 1.40% 
RSD % Recovery    = 0.01 
LOD = 0.63 µg /mL 
LOQ = 2.00 µg /mL 
Correlation coefficient 0.9993 
 
Table 5. Inter-day precision and accuracy parameters for HPLC method (n=6) 
Insulin conc. 
actual 
(µg/mL) 
Amount 
measured on 
day 1 (µg/mL) 
RSD 
 
Amount 
measured on 
day 2  (µg/mL) 
RSD 
  
Overall 
RSD 
  
50  51.31 ± 2.55  0.05  56.03 ± 4.37  0.08  0.08 
200  197.60 ± 10.14  0.05  202.43 ± 3.71  0.02 0.04 
400  380.55 ± 22.20  0.06  397.27 ± 15.18  0.04  0.05 
500  506.90 ± 47.67  0.09 457.48 ± 30.44  0.07  0.09 
1000  1005.57 ± 68.56  0.06  1012.82 ± 55.61  0.05  0.06 
 Limit of Detection & Limit of Quantification 
The LOD and LOQ were calculated from the signal-to-noise ratio, as well as from the standard deviation of the 
response and the slope and were found to be 0.63 and 2.00 µg/mL respectively (Table 4). Thus the lowest 
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amount of insulin that can be detected and quantified respectively, within the limits of accuracy and precision, 
using this method are 0.63 and 2.0 μg/mL [5, 17]. 
 Inter-laboratory Method Validation 
The HPLC method was validated according to ICH guidelines by independent operators in different 
laboratories, using different HPLC systems; on the same day and on three different days, to assess the 
method’s reproducibility. For the first site, retention time was 3.70 ± 0.03 mins, with a peak well resolved from 
the solvent front (Figure). Regression analysis yielded equation of the line as y = 0.0851x - 1.2928 and R2 = 
0.9998. Intra-day and inter-day results are presented in Table 6 and Table 7 respectively. From here, it can be 
seen that the method was reproducible with %RSD of 1-3%. Similar results obtained from the second site are 
depicted in Table 8. Thus this method could be reproduced in any laboratory and employed for the 
quantification of insulin from samples. 
 
Figure 11. Representative chromatogram of insulin elution during inter-laboratory validation of HPLC method 
at Liverpool John Moores University, UK. A well separated insulin peak with no interference from the mobile 
phase was seen.  
Table 6. Intra-day HPLC validation parameters for insulin method carried out by an independent operator at 
Liverpool John Moores University, using a different HPLC system on the same day, to assess method 
reproducibility (n=3) 
S.N. Insulin conc. 
actual (µg/mL) 
Insulin conc. 
calculated (µg/mL) 
RSD Recovery (%) RSD 
1 62.5 55.60 ± 1.10 0.02 88.95 ± 1.76 0.02 
2 125.0 120.01 ± 1.30 0.01 96.01 ± 1.04 0.01 
3 250.0 254.47 ± 6.07 0.02 101.83 ± 2.43 0.02 
4 500.0 513.29 ± 13.14 0.03 102.66 ± 2.63 0.03 
5 1000.0 1003.48 ± 23.84 0.03 100.35 ± 2.38 0.02 
Mean % recovery      =    97.96 ± 5.65 
RSD % Recovery      =    0.02 
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LOD = 0.53 µg /mL 
LOQ = 1.78 µg /mL 
Correlation coefficient  0.9998  
 
Table 7. Inter-day precision and accuracy parameters carried out by an independent operator at Liverpool 
John Moores University, using a different HPLC system on three different days, to assess method 
reproducibility (n=9) 
Insulin 
conc. 
actual 
(µg/mL) 
Amount 
measured on 
day 1 (µg/mL) 
Amount 
measured on 
day 2  (µg/mL) 
Amount 
measured on 
day 3  (µg/mL) 
Overall 
amount 
measured 
(µg/mL) 
Overall 
RSD 
62.5 55.60 ± 1.10 57.51 ± 2.98 59.43 ± 3.00 57.51 ± 1.91 0.03 
125.0 120.01 ± 1.30 123.40 ± 2.79 125.28 ± 6.81 122.90 ± 2.67 0.02 
250.0 254.47 ± 6.07 259.08 ± 3.28 257.82 ± 10.57 257.16 ± 2.33 0.01 
500.0 513.29 ± 13.14 521.10 ± 4.14 516.62 ± 22.13 517.00 ± 3.92 0.01 
1000.0 1003.48 ± 23.84 985.23 ± 10.22 985.94 ± 4.07 991.54± 10.34 0.01 
 
Mean % recovery = 96.06 ± 8.29% 
RSD % Recovery = 0.09 
  
Table 8. Intra-day HPLC validation parameters for insulin method carried out by an independent operator at 
the University of Wolverhampton, using a different HPLC system on the same day, to assess method 
reproducibility (n=3) 
S.N. Insulin conc. 
actual (µg/mL) 
Insulin conc. 
calculated (µg/mL) 
RSD Recovery (%) RSD 
1 62.5 62.11 ± 2.19 0.04 98.38 ± 3.50 0.04 
2 125.0 123.82 ± 2.43 0.02 99.06 ± 1.95 0.02 
3 250.0 246.95 ± 11.10 0.04 98.78 ± 4.44 0.04 
4 500.0 506.26 ± 16.73 0.03 101.25 ± 3.35 0.03 
5 1000.0 997.81 ± 47.11 0.05 99.78 ± 4.71 0.05 
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Mean % recovery      =    99.65 ± 0.97 
RSD % Recovery      =    0.01 
LOD = 0.74 µg /mL 
LOQ = 2.47 µg /mL 
 
Correlation coefficient  0.9999  
 
 Stability of Insulin Solutions  
Results of stability of 1000 μg/mL insulin solutions stored in the fridge for 72 hours are shown in Table 9. The 
percent recovery was calculated using the regression equation of the calibration curve. ANOVA for the peak 
areas and amount of insulin measured on both days showed no significant difference (p>0.05). The overall 
RSD of 7.94 – 8.07% shows that insulin solutions can be stored in the fridge for up to three days without 
deterioration. This is in line with results obtained by Moussa et al [10], who reported that insulin solutions 
remained stable in the fridge for up to 5 days. 
Table 9. Stability of 1000 μg/mL insulin solutions after storage at 2-8 °C for 72 hours (n=3). Results showed 
that insulin solutions were stable for 3 days when stored in the fridge. 
 Day 0 Day 3 Overall RSD 
Peak Area 
(mAU) 
62.32 
67.80 
54.15 
62.32 
61.37 
56.14 
8.07 
Amount 
measured 
1054.78 
1145.52 
919.45 
1052.54 
1036.66 
949.26 
7.94 
 
Conclusions 
The aim of this work was to describe the steps involved in our optimisation and validation of a simple, rapid 
and efficient method for insulin quantification by HPLC, which could be reproduced in any laboratory at room 
temperature. Insulin was effectively eluted at 3.8 mins with no interference from the solvent front. The method 
was validated in our laboratories and independent operator laboratories with similar results that complied with 
the ICH guidelines for HPLC method validation. Thus, the developed method is rapid with short runtime, at 
room temperature with simple UV detectors, and low detection and quantification limits, which can be 
employed for the HPLC quantification of insulin from any sample with high reproducibility from other 
laboratories. 
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